RxDoctor Payments Data

Edward Baptista, MD

Cardiovascular Disease · Humble, TXNPI 1487762209

Payments from drug & device makers

$15,967in general payments, 2019–2025

Across 815 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Boston Scientific$2K
  • Abbott$2K
  • E.r. Squibb & Sons, L.L.C.$771
  • Merck$710
  • Johnson & Johnson$707
  • plus $8K from 46 others

What the payments were for

  • Food & beverage$15,86399%
  • Education$1041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,967 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$231,435
Medicare patients
1,109
Services billed
3,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban393$422,384
XareltoRivaroxaban174$188,453
AdempasRiociguat12$162,379
EntrestoSacubitril/Valsartan108$131,697
Repatha SureclickEvolocumab56$48,248
FarxigaDapagliflozin Propanediol39$47,475
BrilintaTicagrelor29$33,791
MultaqDronedarone Hcl12$22,893
Praluent PenAlirocumab15$21,034
VascepaIcosapent Ethyl26$20,877
JardianceEmpagliflozin21$18,707
Ranolazine ErRanolazine81$11,441
NexletolBempedoic Acid12$11,169
Repatha PushtronexEvolocumab13$8,461
Icosapent Ethyl26$7,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$437$422,384393 claims
Johnson & JohnsonXarelto$707$188,453174 claims
BayerAdempas$19$162,37912 claims
NovartisEntresto$1,991$131,697108 claims
AstraZenecaFarxiga, Brilinta$311$81,26668 claims
Sanofi-aventis U.S. LLCMultaq$292$22,89312 claims
Boehringer IngelheimJardiance$155$18,70721 claims
Esperion Therapeutics, Inc.Nexletol$588$11,16912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →